drugset
drugset / Trial / NCT06888232

Safety and Efficacy of Immunomodulator Drug Thalidomide in Multi-transfused Thalassemia Patients

NCT06888232 ↗

Completed 121 enrolled Muhammad Aamir Latif
NaSingle-groupOpen-labelTreatment

Summary

This study aimed to determine the safety and efficacy of thalidomide in multi-transfused thalassemic children.

Timeline

Start
2023-08-01
Primary completion
2024-12-31
Completion
2024-12-31

Drugs

EvaluationDrugModalityDoseRoute
Subject Thalidomide Other / unclassified 1.5 mg/kg —

Indications

thalassemia